Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.53M | -20.39M | -19.91M | -25.04M | -23.40M |
| Total Depreciation and Amortization | 1.30M | 1.32M | 1.34M | 1.36M | 1.46M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.93M | 3.45M | 5.26M | 3.12M | 11.12M |
| Change in Net Operating Assets | -6.25M | -5.64M | -7.94M | -2.28M | -15.46M |
| Cash from Operations | -23.55M | -21.25M | -21.25M | -22.84M | -26.28M |
| Capital Expenditure | -85.00K | -74.00K | -127.00K | -288.00K | -334.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 37.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.45M | 27.44M | 19.16M | 25.02M | 28.88M |
| Cash from Investing | 32.37M | 27.36M | 19.07M | 24.73M | 28.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 93.00K | 0.00 | 109.00K | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -19.00K | -187.00K | -275.00K | -77.00K | -- |
| Cash from Financing | 74.00K | -187.00K | -166.00K | -77.00K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.89M | 5.92M | -2.35M | 1.81M | 2.27M |